4881 Stock Overview
Engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
FunPep Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥181.00 |
| 52 Week High | JP¥325.00 |
| 52 Week Low | JP¥118.00 |
| Beta | 0.70 |
| 11 Month Change | 16.03% |
| 3 Month Change | 19.08% |
| 1 Year Change | -2.16% |
| 33 Year Change | -56.28% |
| 5 Year Change | n/a |
| Change since IPO | -76.79% |
Recent News & Updates
Shareholder Returns
| 4881 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 3.4% | -0.09% | 2.4% |
| 1Y | -2.2% | 0.2% | 24.6% |
Return vs Industry: 4881 underperformed the JP Biotechs industry which returned -1.1% over the past year.
Return vs Market: 4881 underperformed the JP Market which returned 24.1% over the past year.
Price Volatility
| 4881 volatility | |
|---|---|
| 4881 Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4881 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4881's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 15 | Toshimi Miyoshi | www.funpep.co.jp |
FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis.
FunPep Company Limited Fundamentals Summary
| 4881 fundamental statistics | |
|---|---|
| Market cap | JP¥4.71b |
| Earnings (TTM) | -JP¥760.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.2x
P/E RatioIs 4881 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4881 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥760.00m |
| Earnings | -JP¥760.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | -29.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4881 perform over the long term?
See historical performance and comparison